Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acadia Pharmaceuticals Inc.
< Previous
1
2
3
4
Next >
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
May 07, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
May 05, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
April 23, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
March 13, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
March 05, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 03, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
February 26, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
December 11, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
December 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
November 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 05, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
September 23, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 28, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.